Review Article
In Vivo Tracking of Cell Therapies for Cardiac Diseases with Nuclear Medicine
Table 2
Preclinical studies that used indirect radiopharmaceutical tracking for cell therapies in models of myocardial infarction.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
123I: iodine-123; 124I: iodine-124; 18F: fluorine-18; Tc: technetium-99m; ADSCs: adipose tissue-derived stem cells; BM-MSCs: bone marrow mesenchymal stem cells; CDCs: cardiac-derived stem/progenitor cells; FHBG: 9-[4-fluoro-3-(hydroxymethyl)butyl]guanine derivatives; iPSCs: induced pluripotent stem cells; SCID: severe combined immunodeficiency. |